---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-11T23:22:02.393532'
end_time: '2026-01-11T23:26:15.973394'
duration_seconds: 253.58
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: PAX6
  gene_symbol: PAX6
  uniprot_accession: P26367
  protein_description: 'RecName: Full=Paired box protein Pax-6; AltName: Full=Aniridia
    type II protein; AltName: Full=Oculorhombin;'
  gene_info: Name=PAX6; Synonyms=AN2;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the paired homeobox family. .
  protein_domains: HD. (IPR001356); Homeobox_CS. (IPR017970); Homeodomain-like_sf.
    (IPR009057); PAIRED_DNA-bd_dom. (IPR043182); Paired_dom. (IPR001523)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 17
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P26367
- **Protein Description:** RecName: Full=Paired box protein Pax-6; AltName: Full=Aniridia type II protein; AltName: Full=Oculorhombin;
- **Gene Information:** Name=PAX6; Synonyms=AN2;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the paired homeobox family. .
- **Key Domains:** HD. (IPR001356); Homeobox_CS. (IPR017970); Homeodomain-like_sf. (IPR009057); PAIRED_DNA-bd_dom. (IPR043182); Paired_dom. (IPR001523)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PAX6" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PAX6' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PAX6** (gene ID: PAX6, UniProt: P26367) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P26367
- **Protein Description:** RecName: Full=Paired box protein Pax-6; AltName: Full=Aniridia type II protein; AltName: Full=Oculorhombin;
- **Gene Information:** Name=PAX6; Synonyms=AN2;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the paired homeobox family. .
- **Key Domains:** HD. (IPR001356); Homeobox_CS. (IPR017970); Homeodomain-like_sf. (IPR009057); PAIRED_DNA-bd_dom. (IPR043182); Paired_dom. (IPR001523)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PAX6" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PAX6' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PAX6** (gene ID: PAX6, UniProt: P26367) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan status: Target identity verified; evidence gathered from 2023–2025 peer‑reviewed sources emphasizing 2023–2024 findings where available. Report below cites only retrieved context.

Comprehensive research report: Human PAX6 (UniProt P26367)

1) Key concepts and definitions
- Gene/protein identity and domains. PAX6 encodes a paired-box transcription factor with two DNA-binding modules: an N‑terminal paired domain (PD) with subdomains (e.g., RED subdomain) and a C‑terminal homeobox/homeodomain; these define the paired homeobox family and enable sequence-specific binding to promoters and enhancers in developmentally regulated genes (human; Homo sapiens). Structural and genetic data emphasize the importance of both PD and homeobox domains for DNA binding and disease, with missense hotspots in the PD (e.g., RED subdomain) altering target recognition (review and primary evidence) (hall2025comprehensiveanalysisof pages 17-18, boehm2023wholegenomesequencingof pages 3-4).
- Biological scope. PAX6 is expressed in the developing central nervous system and eye, and in pancreatic endocrine lineages; it functions as a transcriptional regulator controlling developmental programs and mature cell function (boehm2023wholegenomesequencingof pages 5-6, hall2025comprehensiveanalysisof pages 17-18).

2) Mechanism of action and localization
- Transcriptional mechanism. In human cells, PAX6 binds promoter/enhancer elements of thousands of genes and can act as both activator and repressor; in pancreatic β cells it controls genes required for exocytosis and glucose‑stimulated insulin secretion (GSIS) (boehm2023wholegenomesequencingof pages 5-6). Missense substitutions in the PD (e.g., p.P81S in RED subdomain) are predicted to perturb helix structure and DNA interaction specificity, consistent with sensitivity of the PD–DNA interface (boehm2023wholegenomesequencingof pages 3-4).
- Subcellular localization. As a sequence‑specific transcription factor, PAX6 exerts its function through chromatin binding at regulatory DNA (promoters/enhancers) in the nucleus; its disease-causing variants are enriched in DNA-binding domains (hall2025comprehensiveanalysisof pages 17-18, boehm2023wholegenomesequencingof pages 5-6).

3) Primary biological functions and pathways (by system)
- Eye development. PAX6 is a master regulator of ocular development, required for lens and retinal programs across vertebrates. Human and comparative vertebrate studies underscore conserved roles in lens gene regulatory networks and retinal progenitor competence; recurrent heterozygous variants cause aniridia and related anterior/posterior segment defects (hall2025comprehensiveanalysisof pages 17-18, mrstakova2024geneticanalysisof pages 15-15). Clinically, detailed phenotyping (including OCT for foveal hypoplasia and ERG) is used to define PAX6-associated disease spectra (hall2025comprehensiveanalysisof pages 17-18).
- Brain development. PAX6 regulates cortical neurogenesis and forebrain patterning; haploinsufficiency in humans associates with cerebral malformations and olfactory dysfunction. Genetic mapping in syndromic deletions places PAX6 in the WAGR critical region with WT1, consistent with neurodevelopmental contributions (joko2025sexdifferenceinolfactory pages 9-9). 
- Pancreatic endocrine function. In human endocrine progenitors and β cells, PAX6 is among the top expressed regulators; it modulates GSIS by controlling exocytotic gene expression. Human genetic evidence supports a dosage effect on β‑cell function (boehm2023wholegenomesequencingof pages 5-6, boehm2023wholegenomesequencingof pages 6-7).

4) Dosage sensitivity, haploinsufficiency, and disease associations
- Congenital aniridia and related ocular disease. Heterozygous loss‑of‑function (LoF) or critical-region deletions that abolish PAX6 expression are the predominant causes of congenital aniridia. Pathogenic mechanisms span nonsense/frameshift, splice variants (including noncoding splice-impacting SNVs), and regulatory deletions; genotype–phenotype correlations highlight severe ocular phenotypes with truncating variants and variable expressivity with missense alleles (review synthesis) (hall2025comprehensiveanalysisof pages 17-18).
- WAGR syndrome. Deletions encompassing PAX6 and WT1 on 11p13 define WAGR; PAX6 contributes ocular/neurodevelopmental features within the critical region (joko2025sexdifferenceinolfactory pages 9-9).
- Diabetes and metabolic risk. Epidemiology across PAX6 mutation cohorts indicates increased diabetes prevalence and age‑dependent penetrance: one study reported type 2 diabetes in 12.8% (11/86) of heterozygous PAX6 mutation carriers—approximately double background—consistent with progressive β‑cell dysfunction (boehm2023wholegenomesequencingof pages 6-7). Family‑based WGS identified a rare PD missense (p.P81S) segregating with autosomal‑dominant adult‑onset diabetes without eye abnormalities, aligning with PAX6’s role in insulin secretion; such missense diabetes alleles appear rare in population data (EJHG 2023) (boehm2023wholegenomesequencingof pages 5-6, boehm2023wholegenomesequencingof pages 3-4, boehm2023wholegenomesequencingof pages 6-7).

5) Recent developments (2023–2024 emphasis)
- Clinical genetics and detection rates. In a 2024 Chinese aniridia cohort (n=60 from 51 families), combined targeted NGS and MLPA identified pathogenic variants in PAX6/adjacent genes in 59 patients with a total detection rate of 98.3%, underscoring the value of adding MLPA to capture copy‑number changes and critical‑region deletions; phenotypic variability occurred within and between families (Orphanet J Rare Dis, Oct 2024; URL: https://doi.org/10.1186/s13023-024-03388-3) (wang2024geneticanalysisusing pages 12-12).
- Expanded systemic insights and updated mutation/phenotype catalogs. Recent reviews synthesize 2019–2024 findings, including novel noncoding variants affecting splicing, PD missense hotspots, recurrent microdeletions of 3′ regulatory regions, and registry-based recognition of systemic features beyond ocular disease (hall2025comprehensiveanalysisof pages 17-18).
- Endocrine genetics. 2023 family WGS refined PAX6’s contribution to adult‑onset diabetes without eye anomalies, linking a conserved PD residue to β‑cell exocytosis pathways and emphasizing ACMG/AMP classification rigor for atypical PAX6 presentations (EJHG; URL: https://doi.org/10.1038/s41431-022-01182-y) (boehm2023wholegenomesequencingof pages 5-6, boehm2023wholegenomesequencingof pages 3-4, boehm2023wholegenomesequencingof pages 6-7).
- Comparative developmental studies. 2024 vertebrate genetic analyses (medaka) highlight conservation of lens programs and divergence in retinal lineage requirements, refining models of PAX6 developmental logic across species (Frontiers in Cell and Developmental Biology; URL: https://doi.org/10.3389/fcell.2024.1448773) (mrstakova2024geneticanalysisof pages 15-15).

6) Current applications and implementations
- Molecular diagnostics. Best practice integrates targeted NGS panels for ocular development genes with MLPA for PAX6/11p13 CNVs to maximize yield and to identify WAGR‑region events; the high (≈98%) detection reported with combined approaches supports routine adoption in clinical laboratories (wang2024geneticanalysisusing pages 12-12).
- Functional interpretation. Domain‑aware variant assessment is essential: PD/homeobox domain substitutions warrant heightened scrutiny given enriched pathogenicity and structural roles in DNA recognition (hall2025comprehensiveanalysisof pages 17-18, boehm2023wholegenomesequencingof pages 3-4).
- Endocrine risk stratification. In carriers of heterozygous PAX6 variants, clinicians should consider periodic assessment for glucose intolerance and diabetes given elevated prevalence and age‑related penetrance (boehm2023wholegenomesequencingof pages 6-7).

7) Expert opinions and authoritative syntheses
- Reviews integrating structural biology, developmental genetics, and clinical genomics emphasize PAX6’s dual DNA-binding domains, haploinsufficiency as the canonical mechanism for aniridia, and the necessity of including noncoding/regulatory lesions in diagnostic pipelines (hall2025comprehensiveanalysisof pages 17-18). Neurodevelopment experts highlight PAX6’s roles in cortical patterning and interhemispheric/olfactory development, and its placement within the WAGR critical region (joko2025sexdifferenceinolfactory pages 9-9).

8) Statistics and quantitative data (recent)
- Diagnostic yield. 98.3% overall detection in a 2024 Chinese aniridia cohort using NGS+MLPA across PAX6/FOXC1/adjacent regions (Orphanet J Rare Dis, 2024; DOI above) (wang2024geneticanalysisusing pages 12-12).
- Diabetes prevalence. 12.8% T2D prevalence among 86 confirmed heterozygous PAX6 mutation carriers—about two‑fold above population prevalence—with age‑dependent penetrance (boehm2023wholegenomesequencingof pages 6-7).

9) Mandatory identity verification (per request)
- Symbol and protein. PAX6 matches the requested human gene; the protein is the paired box protein PAX6 (paired + homeobox DNA‑binding domains), consistent with UniProt P26367 description and family assignment (hall2025comprehensiveanalysisof pages 17-18).
- Organism. All cited primary/clinical studies and reviews above concern Homo sapiens unless noted as comparative vertebrate models; human disease and functional data are specifically highlighted (boehm2023wholegenomesequencingof pages 5-6, wang2024geneticanalysisusing pages 12-12, hall2025comprehensiveanalysisof pages 17-18).
- Domains/family. Literature confirms membership in the paired homeobox family and the presence of PD and homeobox domains central to function and pathogenic variation (hall2025comprehensiveanalysisof pages 17-18, boehm2023wholegenomesequencingof pages 3-4).
- Ambiguity check. No conflicting non‑human or alternative “PAX6” gene symbols were used for the human evidence synthesized here; where non‑human models are referenced, they are explicitly noted as comparative (mrstakova2024geneticanalysisof pages 15-15).

10) Practical summary for functional annotation
- Molecular function. Sequence-specific DNA-binding transcription factor with dual PD and homeobox domains; binds and regulates promoters/enhancers of developmental and endocrine effector genes, acting as activator/repressor in a context-dependent manner (boehm2023wholegenomesequencingof pages 5-6, hall2025comprehensiveanalysisof pages 17-18).
- Biological process. Eye morphogenesis (lens/retina), cortical neurogenesis/forebrain patterning, pancreatic endocrine differentiation and mature β‑cell stimulus–secretion coupling (boehm2023wholegenomesequencingof pages 5-6, hall2025comprehensiveanalysisof pages 17-18, joko2025sexdifferenceinolfactory pages 9-9).
- Cellular component. Nuclear chromatin at cis‑regulatory elements (inferred from transcription factor activity and domain-centric pathogenicity) (hall2025comprehensiveanalysisof pages 17-18, boehm2023wholegenomesequencingof pages 5-6).
- Pathways/targets. Programs controlling lens crystallin networks and retinal progenitor competence (developmental), and β‑cell exocytosis machinery underlying GSIS (functional) (mrstakova2024geneticanalysisof pages 15-15, boehm2023wholegenomesequencingof pages 5-6).
- Disease mechanism. Haploinsufficiency due to LoF coding variants or regulatory deletions is the predominant cause of congenital aniridia; specific missense variants in DNA-binding domains can shift phenotypes from ocular malformation to metabolic dysfunction, reflecting altered DNA-binding specificity and dosage (hall2025comprehensiveanalysisof pages 17-18, boehm2023wholegenomesequencingof pages 5-6, boehm2023wholegenomesequencingof pages 3-4, boehm2023wholegenomesequencingof pages 6-7).

Key source list with URLs and dates
- Hall J, et al. Comprehensive analysis of congenital aniridia and differential diagnoses. Ophthalmology and Therapy. Mar 2025. URL: https://doi.org/10.1007/s40123-025-01122-1 (hall2025comprehensiveanalysisof pages 17-18).
- Boehm BO, et al. Whole-genome sequencing… PAX6 missense in adult‑onset diabetes. Eur J Hum Genet. Oct 2023. URL: https://doi.org/10.1038/s41431-022-01182-y (boehm2023wholegenomesequencingof pages 5-6, boehm2023wholegenomesequencingof pages 3-4, boehm2023wholegenomesequencingof pages 6-7).
- Wang L, et al. Genetic analysis using NGS and MLPA in Chinese aniridia. Orphanet J Rare Dis. Oct 2024. URL: https://doi.org/10.1186/s13023-024-03388-3 (wang2024geneticanalysisusing pages 12-12).
- Joko N, et al. Sex-difference in olfactory interhemispheric malformation caused by pax6 haploinsufficiency. Tohoku J Exp Med. Jun 2025. URL: https://doi.org/10.1620/tjem.2025.j068 (joko2025sexdifferenceinolfactory pages 9-9).
- Mrstakova SM, Kozmik Z. Genetic analysis of medaka Pax6 roles in vertebrate eye development. Front Cell Dev Biol. Oct 2024. URL: https://doi.org/10.3389/fcell.2024.1448773 (mrstakova2024geneticanalysisof pages 15-15).

Notes and limitations
- Pioneer‑factor specific mechanisms and CRISPR/base‑editing therapeutic advances for PAX6 are active areas, but detailed mechanistic or interventional data were not available in the retrieved, citable context here. Where comparative models were cited, human relevance was explicitly separated. Future updates should integrate targeted mechanistic studies and clinical trial reports as they emerge.

References

1. (hall2025comprehensiveanalysisof pages 17-18): Jonathan Hall, Marta Corton, Fabian Norbert Fries, Jessica Obst, Clara Grünauer-Kloevekorn, Berthold Seitz, Maria della Volpe Waizel, Eszter Jávorszky, Kálmán Tory, Erika Maka, Maryam Amini, Shweta Suiwal, Tanja Stachon, and Nóra Szentmáry. Comprehensive analysis of congenital aniridia and differential diagnoses: genetic insights and clinical manifestations. Ophthalmology and Therapy, 14:835-856, Mar 2025. URL: https://doi.org/10.1007/s40123-025-01122-1, doi:10.1007/s40123-025-01122-1. This article has 5 citations and is from a peer-reviewed journal.

2. (boehm2023wholegenomesequencingof pages 3-4): Bernhard O. Boehm, Wolfgang Kratzer, and Vikas Bansal. Whole-genome sequencing of multiple related individuals with type 2 diabetes reveals an atypical likely pathogenic mutation in the pax6 gene. European Journal of Human Genetics, 31:89-96, Oct 2023. URL: https://doi.org/10.1038/s41431-022-01182-y, doi:10.1038/s41431-022-01182-y. This article has 5 citations and is from a domain leading peer-reviewed journal.

3. (boehm2023wholegenomesequencingof pages 5-6): Bernhard O. Boehm, Wolfgang Kratzer, and Vikas Bansal. Whole-genome sequencing of multiple related individuals with type 2 diabetes reveals an atypical likely pathogenic mutation in the pax6 gene. European Journal of Human Genetics, 31:89-96, Oct 2023. URL: https://doi.org/10.1038/s41431-022-01182-y, doi:10.1038/s41431-022-01182-y. This article has 5 citations and is from a domain leading peer-reviewed journal.

4. (mrstakova2024geneticanalysisof pages 15-15): Simona Mikula Mrstakova and Zbynek Kozmik. Genetic analysis of medaka fish illuminates conserved and divergent roles of pax6 in vertebrate eye development. Frontiers in Cell and Developmental Biology, Oct 2024. URL: https://doi.org/10.3389/fcell.2024.1448773, doi:10.3389/fcell.2024.1448773. This article has 4 citations and is from a poor quality or predatory journal.

5. (joko2025sexdifferenceinolfactory pages 9-9): Natsumi Joko, Takako Kikkawa, Takayoshi Inoue, and Noriko Osumi. Sex-difference in olfactory interhemispheric malformation caused by pax6 haploinsufficiency. The Tohoku journal of experimental medicine, Jun 2025. URL: https://doi.org/10.1620/tjem.2025.j068, doi:10.1620/tjem.2025.j068. This article has 1 citations.

6. (boehm2023wholegenomesequencingof pages 6-7): Bernhard O. Boehm, Wolfgang Kratzer, and Vikas Bansal. Whole-genome sequencing of multiple related individuals with type 2 diabetes reveals an atypical likely pathogenic mutation in the pax6 gene. European Journal of Human Genetics, 31:89-96, Oct 2023. URL: https://doi.org/10.1038/s41431-022-01182-y, doi:10.1038/s41431-022-01182-y. This article has 5 citations and is from a domain leading peer-reviewed journal.

7. (wang2024geneticanalysisusing pages 12-12): Li Wang, Qingdan Xu, Wentao Wang, Xinghuai Sun, and Yuhong Chen. Genetic analysis using next-generation sequencing and multiplex ligation probe amplification in chinese aniridia patients. Orphanet Journal of Rare Diseases, Oct 2024. URL: https://doi.org/10.1186/s13023-024-03388-3, doi:10.1186/s13023-024-03388-3. This article has 3 citations and is from a peer-reviewed journal.

## Citations

1. boehm2023wholegenomesequencingof pages 5-6
2. boehm2023wholegenomesequencingof pages 3-4
3. hall2025comprehensiveanalysisof pages 17-18
4. joko2025sexdifferenceinolfactory pages 9-9
5. boehm2023wholegenomesequencingof pages 6-7
6. wang2024geneticanalysisusing pages 12-12
7. mrstakova2024geneticanalysisof pages 15-15
8. https://doi.org/10.1186/s13023-024-03388-3
9. https://doi.org/10.1038/s41431-022-01182-y
10. https://doi.org/10.3389/fcell.2024.1448773
11. https://doi.org/10.1007/s40123-025-01122-1
12. https://doi.org/10.1620/tjem.2025.j068
13. https://doi.org/10.1007/s40123-025-01122-1,
14. https://doi.org/10.1038/s41431-022-01182-y,
15. https://doi.org/10.3389/fcell.2024.1448773,
16. https://doi.org/10.1620/tjem.2025.j068,
17. https://doi.org/10.1186/s13023-024-03388-3,